TY - JOUR
T1 - Milacemide
T2 - A Placebo‐Controlled Study in Senile Dementia of the Alzheimer Type
AU - Dysken, Maurice W.
AU - Mendels, Joseph
AU - LeWitt, Peter
AU - Reisberg, Barry
AU - Pomara, Nunzio
AU - Wood, James
AU - Skare, Stacy
AU - Fakouhi, J. Daniel
AU - Herting, Robert L.
PY - 1992/5
Y1 - 1992/5
N2 - Milacemide, a MAO‐B inhibitor that is also a prodrug for glycine, was tested as a treatment for senile dementia of the Alzheimer type (SDAT) because of its potential for enhancing cognition in animal models of impaired learning and memory. Double‐blind, placebo‐controlled, randomized clinical trial. Sixteen study sites, both university‐affiliated and private. A total of 228 outpatients (116 men and 112 women) with SDAT, ranging in age from 49–93 years. Intervention: 1200 mg/day milacemide treatment for 1 month (113 patients received milacemide, and 115 patients received placebo). Alzheimer's Disease Assessment Scale and the Mini‐Mental State Examination. Milacemide‐treated SDAT patients did not show significant improvement in any of the outcome measures used. Significant elevations in liver enzymes in four subjects were of sufficient magnitude to necessitate withdrawal from the study. Milacemide does not appear to be an effective treatment in enhanci g cognition in SDAT patients.
AB - Milacemide, a MAO‐B inhibitor that is also a prodrug for glycine, was tested as a treatment for senile dementia of the Alzheimer type (SDAT) because of its potential for enhancing cognition in animal models of impaired learning and memory. Double‐blind, placebo‐controlled, randomized clinical trial. Sixteen study sites, both university‐affiliated and private. A total of 228 outpatients (116 men and 112 women) with SDAT, ranging in age from 49–93 years. Intervention: 1200 mg/day milacemide treatment for 1 month (113 patients received milacemide, and 115 patients received placebo). Alzheimer's Disease Assessment Scale and the Mini‐Mental State Examination. Milacemide‐treated SDAT patients did not show significant improvement in any of the outcome measures used. Significant elevations in liver enzymes in four subjects were of sufficient magnitude to necessitate withdrawal from the study. Milacemide does not appear to be an effective treatment in enhanci g cognition in SDAT patients.
UR - http://www.scopus.com/inward/record.url?scp=0026631288&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026631288&partnerID=8YFLogxK
U2 - 10.1111/j.1532-5415.1992.tb02019.x
DO - 10.1111/j.1532-5415.1992.tb02019.x
M3 - Article
C2 - 1634705
AN - SCOPUS:0026631288
SN - 0002-8614
VL - 40
SP - 503
EP - 506
JO - Journal of the American Geriatrics Society
JF - Journal of the American Geriatrics Society
IS - 5
ER -